The evolution of long-acting antipsychotic treatments

The evolution of long-acting antipsychotic treatments

Saved in:

Bibliographic Details
Main Authors:	Sofia Pappa, Robin Emsley
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Series:	Therapeutic Advances in Psychopharmacology
Online Access:	https://doi.org/10.1177/20451253241305610
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Procyclidine Use with Long-Acting Injectable Antipsychotics
by: Prabin Gautam, et al.
Published: (2025-06-01)

Procyclidine Use in Long-Acting Injectable Antipsychotics
by: Shalina Mitchell, et al.
Published: (2025-06-01)

Long-Acting Antipsychotic Injections: Prescribing Practices Across BCUHB
by: Laura Robbins, et al.
Published: (2025-06-01)

Long-term outcomes of Aripiprazole long-acting injectable: a 10-year mirror image study of patient acceptability and treatment effectiveness
by: Joshua Barnett, et al.
Published: (2025-06-01)

Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
by: Salvatore Cipolla, et al.
Published: (2025-03-01)

The Early Use of Long-acting Injectable Antipsychotic Drugs in the Treatment of Bipolar Disorder: A Call for Action
by: Shih-Ku Lin
Published: (2025-04-01)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
by: Lulu Lian, et al.
Published: (2022-01-01)

Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al.

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
by: Citrome L, et al.
Published: (2025-03-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Comparative Analysis of Time to All-cause Treatment Discontinuation and Rehospitalization among Early-phase Schizophrenia Patients Discharged on Long-acting Injectable Antipsychotics versus Oral Antipsychotics
by: Ta-Chun Lin, et al.
Published: (2025-01-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
by: Madhav P. Bhatta, et al.
Published: (2021-05-01)

Financial incentives and long-acting injectable antipsychotics engagement: community mental health professionals’ perspectives
by: Nathan Hodson, et al.
Published: (2025-08-01)

Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics
by: Philip Bediako-Kakari, et al.
Published: (2025-05-01)

Enhanced treatment outcomes for schizophrenia through combined long-acting injectable antipsychotic medications and home visits: retrospective cohort study
by: Hiroyuki Harada, et al.
Published: (2025-09-01)

Do Long-Acting Injectable Antipsychotics Influence Serum Levels of Brain-Derived Neurotrophic Factor in People With Schizophrenia and Schizoaffective Disorder?
by: Mirko Manchia, et al.
Published: (2024-01-01)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
by: de Bartolomeis A, et al.
Published: (2016-01-01)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
by: Haishan Wu, et al.
Published: (2013-01-01)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
by: Karson C, et al.
Published: (2016-01-01)

Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report
by: Xiaobo Xie, et al.
Published: (2025-01-01)

Treatment of tardive dyskinesia caused by long-term antipsychotic use: case reports and literature review
by: I. Pabarčiūtė, et al.
Published: (2020-12-01)

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

The Importance of Antipsychotic Treatment in Severe Mental Disorders
by: Pasquale Paribello, et al.
Published: (2025-03-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Antipsychotics and rashes
by: Jessica Lin
Published: (2018-11-01)

The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China
by: Huaning Wang, et al.
Published: (2025-07-01)

Retrospective cohort study of long-acting injectable (LAI) antipsychotic initiation in the inpatient setting: impact of LAI characteristics on transition and continuation of care among patients with schizophrenia in the USA
by: Rashmi Patel, et al.
Published: (2025-03-01)

The use of antipsychotics in the treatment of catatonia: a systematic review
by: Maximilien Redon, et al.
Published: (2025-01-01)

The Effects of SSRIs and Antipsychotics on Long COVID Development in a Large Veteran Population
by: Jerry Bradley, et al.
Published: (2024-10-01)

MULTIPLEX ANALYSIS OF PERIPHERAL BIOMARKERS IN SCHIZOPHRENIC PATIENTS WITH LONG-TERM ANTIPSYCHOTIC THERAPY
by: A. S. Boiko, et al.
Published: (2019-01-01)

Choice of Treatment Used in a Patient With Antipsychotic-Induced Rhabdomyolysis
by: Mizanoor Rahman, et al.
Published: (2025-06-01)

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies [Corrigendum]
by: Sajatovic M, et al.
Published: (2025-06-01)

Synthesis of Thienopyrimidines and their Antipsychotic Activity
by: Chanchal Sharma, et al.
Published: (2010-01-01)

The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease
by: Nevena Divac, et al.
Published: (2016-01-01)

Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
by: A. R. Asadullin, et al.
Published: (2025-06-01)

Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
by: Callisia N. Clarke, et al.
Published: (2023-12-01)

Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy
by: Stanković Žana, et al.
Published: (2013-01-01)

Combined Audit for depot/LAI (Long-Acting Injectable) Antipsychotic Medications Relapse Prevention and Side Effects for Older Adult Populations (Pan Trust Audit – Black Country Healthcare NHS Foundation Trust)
by: Sui Yung Chen, et al.
Published: (2025-06-01)

Exploring Patient, Caregiver, and Prescriber Preferences for an Injectable Antipsychotic Administered Every 2 Months for the Maintenance Treatment of Schizophrenia: A Multicenter Qualitative Interview Study Conducted in Europe
by: Pappa S, et al.
Published: (2025-04-01)